Boston Scientific Announces Agreement With DOJ On Pre-Acquisition Investigation ...(--- ---- Adjusted results ...),Health

Date:11/6/2009

--- ---- Adjusted results $291 $0.19 $291 $0.19 ==== ===== ==== ===== * Assumes dilution of 10.9 million shares for all or a portion of these amounts. Nine Months Ended September 30, 2009 ------------------------------------ Previously Reported As Updated ----------- ---------- Impact Impact per per In millions, except per share Net diluted Net diluted data income share income share ----------------------------- ------ ----- ------ ----- GAAP results $345 $0.23 $51 $0.03 Non-GAAP adjustments: Intangible asset impairment charges 8 0.01 8 0.01 Acquisition-related charges 17 0.01 17 0.01 Divestiture-related gains (2) (0.00) (2) (0.00) Restructuring-related charges 69 0.05 69 0.05 Litigation-related net charges 203 0.13 497 0.33 Discrete tax items (74) (0.05) (74) (0.05) Amortization expense 312 0.20 312 0.20 --- ---- --- ---- Adjusted results $878 $0.58 $878 $0.58 ==== ===== ==== =====

An explanati
'/>"/>

SOURCE Boston Scientific Corporation Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17
Related medicine technology :

1. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
2. Boston Scientific Announces Schedule for European Society of Cardiology Congress 2007
3. Boston University Biomedical Engineers Find Chink in Bacterias Armor
4. Boston Scientific to Release Broad Range of Clinical Trial Data Reinforcing Safety and Efficacy of Taxus(R) Coronary Stent Systems at TCT 2007
5. Preliminary Results of Randomized Pilot Study Show Comparable Efficacy for OrbusNeichs Genous(TM) Bio-engineered R Stent(TM) and Boston Scientifics Taxus(R) Stent in Patients at High Risk of Restenosis
6. Boston Scientific PROMUS(TM) and TAXUS(R) Stents Continue Strong Performance in Safety and Efficacy Measures
7. Boston Scientifics Next-Generation Stent Shows Improved Clinical Outcomes in Complex Lesions
8. Positive Five-Year Safety Data for TAXUS(R) Stent Reported in Boston Scientific Trial
9. Boston Scientific Carotid Artery Stenting Trials Produce Positive Three-Year Results
10. Award-Winning Medicine Wheel Returns to the Cyclorama at the Boston Center for the Arts on Dec. 1 for 24-hour Vigil Recognizing World AIDS Day
11. Boston Scientific Announces CE Mark Approval for New Devices to Treat Heart Failure and Sudden Cardiac Death